US Patent Issued to Incyte on Oct. 14 for "Combination therapy for treatment of myeloproliferative neoplasms" (New Jersey, Delaware Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,440,495, issued on Oct. 14, was assigned to Incyte Corp. (Wilmington, Del.).

"Combination therapy for treatment of myeloproliferative neoplasms" was invented by Matthew Stubbs (Woolwich, N.J.) and Phillip C. Liu (Wilmington, Del.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic."

The patent was filed on Oct. 26, 2023,...